AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Keros Therapeutics Inc (NASDAQ:KROS)
15.09 USD
-0.020 0.132%| Previous Close (in USD) | 15.11 |
|---|---|
| Change | -0.020 0.132% |
| 52 W H/L (in USD) | 73.000/27.020 |
| EBITDA (in USD) | -178.63M |
| PE Ratio | -- |
| Volume | 201071 |
| Diluted Eps TTM | -5.18 |
| Total Assets (in USD) | 370.025M |
|---|---|
| Total Liabilities (in USD) | 37.812M |
| Revenue TTM (in USD) | 0.234M |
| Cash (in USD) | 331.147M |
| Market Cap (in USD) | 1,759.090 M |
| Revenue Per Share TTM | 0.007 |
| Gross Profit TTM (in USD) | -87.265M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Employees: 141
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Jasbir S. Seehra Ph.D. | Pres, CEO, Treasurer, & Director | 1956 |
| 2. | Mr. Keith C. Regnante MBA | Chief Financial Officer | 1970 |
| 3. | Dr. Jennifer Lachey Ph.D. | Chief Scientific Officer | 1973 |
| 4. | Mr. Christopher Rovaldi M.Sc. | Chief Operating Officer | 1974 |
| 5. | Ms. Esther Cho J.D. | Head of Legal & Corp. Sec. | NA |
| 6. | Ms. Robin Wagner | VP of HR | NA |
| 7. | Dr. Simon Cooper MBBS | Chief Medical Officer | 1970 |
| 8. | Dr. Jasbir S. Seehra Ph.D. | President, CEO, Treasurer, & Director | 1956 |
| 9. | Mr. Christopher Rovaldi M.Sc. | Chief Operating Officer | 1975 |
| 10. | Ms. Esther Cho J.D. | Senior VP, General Counsel & Secretary | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -104.679M | -56.733M | -45.533M | -12.336M | -1.078M |
| Minority Interest | - | - | - | - | - |
| Net Income | -104.68M | -58.744M | -45.361M | -12.344M | -1.335M |
| Selling General Administrative | 27.525M | 21.33M | 12.797M | 3.184M | 1.58M |
| Gross Profit | - | 20.1M | - | 10M | 10M |
| Reconciled Depreciation | 0.674M | 0.378M | 0.278M | 0.208M | 0.153M |
| Ebit | -114.79M | -56.373M | -46.657M | -10.563M | -1.321M |
| Ebitda | -104.678M | -56.729M | -45.527M | -9.797M | -1.168M |
| Depreciation And Amortization | 10.112M | -0.356M | 1.13M | 0.766M | 0.153M |
| Operating Income | -114.79M | -56.373M | -46.657M | -10.563M | -1.691M |
| Other Operating Expenses | 107.709M | 76.473M | 44.197M | 20.005M | 11.321M |
| Interest Expense | 0.001M | 0.004M | 0.006M | 0.008M | 0.006M |
| Tax Provision | 0M | 2.011M | -0.172M | 0M | 0.257M |
| Interest Income | - | - | - | 2.572M | 0.037M |
| Net Interest Income | -0.001M | -0.004M | -0.006M | -0.008M | 0.006M |
| Income Tax Expense | 0.001M | 2.011M | -0.172M | 0.008M | 0.257M |
| Total Revenue | 0M | 20.1M | 0M | 10M | 10M |
| Total Operating Expenses | 107.709M | 76.473M | 44.197M | 20.005M | 11.321M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 10.111M | -0.36M | 1.124M | -1.773M | 0.237M |
| Net Income From Continuing Ops | -104.679M | -58.744M | -45.361M | -12.336M | -1.335M |
| Net Income Applicable To Common Shares | -104.679M | -58.744M | -45.361M | -14.136M | -2.346M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 370.025M | 306.781M | 255.251M | 269.443M | 10.955M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.001M | 6.719M | 0.34M | 0.16M | 0.226M |
| Total Liab | 37.812M | 29.358M | 12.077M | 7.722M | 5.504M |
| Total Stockholder Equity | 332.213M | 277.423M | 243.174M | 261.721M | 5.451M |
| Other Current Liab | 0.665M | 12.753M | 0.204M | 0.218M | 0.107M |
| Common Stock | 0.003M | 0.002M | 0.002M | 0.002M | 0.002M |
| Capital Stock | 0.003M | 0.002M | 0.002M | 0.002M | 0.002M |
| Retained Earnings | -381.426M | -228.434M | -123.755M | -65.011M | -19.65M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 3.445M | 1.409M | 0.993M | 0.115M |
| Cash | 331.147M | 279.048M | 230.042M | 265.876M | 7.02M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 24.373M | 16.547M | 11.846M | 7.184M | 4.486M |
| Current Deferred Revenue | 17.253M | - | 7.135M | 4.394M | 1.915M |
| Net Debt | -316.703M | -265.782M | -228.949M | -264.977M | -5.745M |
| Short Term Debt | 1.005M | 0.455M | 0.862M | 0.423M | 0.376M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 14.444M | 13.266M | 1.093M | 0.899M | 1.275M |
| Other Stockholder Equity | 713.636M | 505.855M | 366.927M | 326.73M | 25.099M |
| Property Plant Equipment | - | 2.021M | 1.335M | 1.602M | 1.913M |
| Total Current Assets | 347.293M | 285.767M | 251.44M | 267.726M | 8.927M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 1.091M | 0.841M | 18M | 0.216M | 0.922M |
| Long Term Debt | - | - | - | - | 4.956M |
| Inventory | 14.054M | -0.841M | 3.058M | - | 0.759M |
| Accounts Payable | 5.45M | 3.339M | 3.645M | 2.149M | 2.088M |
| Accumulated Other Comprehensive Income | 0M | - | - | -269.443M | -0.453M |
| Non Currrent Assets Other | 2.052M | 3.445M | 1.409M | 0.115M | 0.115M |
| Non Current Assets Total | 22.732M | 21.014M | 3.811M | 1.717M | 2.028M |
| Capital Lease Obligations | 14.444M | 13.266M | 1.093M | 0.899M | 1.275M |
| Long Term Debt Total | - | - | - | - | 4.956M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -1.241M | -1.024M | -0.294M | -0.271M | -0.217M |
| Total Cashflows From Investing Activities | -1.241M | -1.024M | -0.294M | -0.271M | -0.217M |
| Total Cash From Financing Activities | 120.309M | 28.55M | 296.044M | 0.014M | 11.463M |
| Net Income | -104.679M | -58.744M | -45.361M | -12.336M | -1.335M |
| Change In Cash | 49.006M | -34.622M | 258.856M | -16.255M | 18.288M |
| Begin Period Cash Flow | 231.369M | 265.991M | 7.135M | 23.39M | 5.102M |
| End Period Cash Flow | 280.375M | 231.369M | 265.991M | 7.135M | 23.39M |
| Total Cash From Operating Activities | -70.062M | -62.148M | -36.894M | -15.998M | 7.042M |
| Depreciation | 0.674M | 0.378M | 0.278M | 0.208M | 0.153M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 1.042M | - | - | - |
| Sale Purchase Of Stock | 120.309M | 28.55M | 299.013M | 0.014M | 11.508M |
| Other Cashflows From Financing Activities | 0.731M | 0.379M | 52.842M | -0.271M | 11.463M |
| Capital Expenditures | 1.241M | 1.024M | 0.294M | 0.271M | 0.217M |
| Change In Working Capital | 14.308M | -16.07M | 2.275M | -6.724M | 7.949M |
| Other Non Cash Items | 0.953M | 0.52M | 1.817M | 2.795M | 0.194M |
| Free Cash Flow | -71.303M | -63.172M | -37.188M | -16.269M | 6.825M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 1 year ago | 927949 |
| 2. | T. Rowe Price New Horizons | 1 year ago | 926383 |
| 3. | US Small-Cap Growth II Equity Comp | 1 year ago | 926383 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 789464 |
| 5. | Fidelity Select Health Care | 1 year ago | 650000 |
| 6. | iShares Russell 2000 ETF | 1 year ago | 595738 |
| 7. | Eventide Healthcare & Life Sciences I | 1 year ago | 580000 |
| 8. | Fidelity Select Biotechnology | 1 year ago | 438529 |
| 9. | Fidelity Advisor Biotechnology I | 1 year ago | 409600 |
| 10. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 407792 |
| 11. | Fidelity Advisor Health Care I | 1 year ago | 400000 |
| 12. | Fidelity Small Cap Growth | 1 year ago | 378307 |
| 13. | Franklin Biotechnology Discv A(acc)USD | 1 year ago | 375335 |
| 14. | Fidelity Series Small Cap Opps | 1 year ago | 368200 |
| 15. | Candriam Eqs L Biotech C USD Cap | 1 year ago | 350000 |
| 16. | Fidelity Small Cap Value Fund | 1 year ago | 350000 |
| 17. | Candriam Global Equities Oncology | 1 year ago | 301981 |
| 18. | Fidelity Advisor Growth Opps M | 1 year ago | 277800 |
| 19. | FIAM Small Cap Core CIT Cl B | 1 year ago | 277100 |
| 20. | Strategic Advisers Fidelity US TtlStk | 1 year ago | 274910 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 1 year ago | 3874204 |
| 2. | BlackRock Inc | 1 year ago | 2036788 |
| 3. | Vanguard Group Inc | 1 year ago | 1545758 |
| 4. | Alkeon Capital Management, LLC | 1 year ago | 1498907 |
| 5. | Orbimed Advisors, LLC | 1 year ago | 1268734 |
| 6. | T. Rowe Price Associates, Inc. | 1 year ago | 1218504 |
| 7. | Darwin Global Management, Ltd. | 1 year ago | 1060427 |
| 8. | State Street Corporation | 1 year ago | 1054367 |
| 9. | Morgan Stanley - Brokerage Accounts | 1 year ago | 925388 |
| 10. | Franklin Resources Inc | 1 year ago | 699425 |
| 11. | ADAR1 Capital Management LLC | 1 year ago | 688316 |
| 12. | Candriam Luxembourg S.C.A. | 1 year ago | 651999 |
| 13. | Nantahala Capital Management, LLC | 1 year ago | 620282 |
| 14. | Woodline Partners LP | 1 year ago | 583792 |
| 15. | Eventide Asset Management, LLC | 1 year ago | 580000 |
| 16. | Redmile Group, LLC | 1 year ago | 552506 |
| 17. | Geode Capital Management, LLC | 1 year ago | 510211 |
| 18. | Goldman Sachs Group Inc | 1 year ago | 410198 |
| 19. | Parkman Healthcare Partners LLC | 1 year ago | 360467 |
| 20. | Deutsche Bank AG | 1 year ago | 358276 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...